Cancer was responsible for around 142 deaths per 100,000 population in the United States in 2022. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated 65,790 deaths among men alone in 2024. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as 99 percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around 81 percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. A recent poll indicated that many U.S. adults believed smoking cigarettes and using other tobacco products increased a person’s risk of developing cancer, but a much smaller percentage believed the same for proven risk factors such as obesity and drinking alcohol.

In 2021, the death rate for leukemia among youth in the United States aged 0 to 19 years was .48 per 100,000 youth. This was a decrease from the death rate of 0.9 per 100,000 recorded in the year 2001. This statistic shows the cancer death rates for the three most common types of cancer among youth aged 0 to 19 years in the United States in 2001, 2011, and 2021.

In 2022, there were an estimated 2.48 million new cases of trachea, bronchus, and lung cancer worldwide. Breast cancer was the second most common cancer type at that time with around 2.3 million new cases worldwide.

Number of new cancer cases

Cancer can be caused by internal factors like genetics and mutations, as well as external factors such as smoking and radiation. It occurs in the presence of uncontrolled growth and spread of abnormal cells. However, many cancer cases could be prevented, for example, by omitting cigarette usage and heavy alcohol consumption. Risk of developing cancer tends to increase with age and is most common in older adults. Nevertheless, cancer can develop in individuals of any age. Cancer can be treated through surgery, radiation, and chemotherapy, among other methods.

In the United States, there will be an estimated two million new cancer cases and 611,720 deaths in 2024. Among U.S. men, prostate cancer and lung and bronchus cancers are the most common cancer types as of 2024, totaling an estimated 299,010 and 116,310 cases, respectively. In women, breast cancer and lung and bronchus cancer are the most common newly diagnosed types, totaling 310,720 and 118,270 cases, respectively.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

https://market.us/wp-content/uploads/2023/04/Breast-Cancer-Market-Value.jpg" alt="">

The rate of liver cancer diagnoses in the United States increases with age. As of 2021, those aged 75 to 79 years had the highest rates of liver cancer. Risk factors for liver cancer include smoking, drinking alcohol, being overweight or obese, and having diabetes. Who is most likely to get liver cancer? Liver cancer in the United States is much more common among men than women. In 2021, there were 12.3 new liver cancer diagnoses among men per 100,000 population, compared to just five new diagnoses per 100,000 women. Concerning race and ethnicity, non-Hispanic American Indians and Alaska Natives and Hispanic have the highest rates of new liver cancer diagnoses. The five-year survival rate for liver cancer in the United States is around 22 percent, however, this rate is much higher among non-Hispanic Asian and Pacific Islanders than other races and ethnicities. Non-Hispanic Asian and Pacific Islanders have a 33 percent chance of surviving the next five years after a liver cancer diagnosis. Deaths from liver cancer In 2020, there were an estimated 20,262 deaths in the United States due to liver cancer. However, the death rate for liver cancer has decreased over the past few years. In the period 1999 to 2020, the death rate for liver cancer reached a high of five deaths per 100,000 population in 2015 but dropped to 4.6 deaths per 100,000 population by 2020. It is estimated that in 2024, there will be over 19,000 liver and intrahepatic bile duct cancer deaths among men in the United States and 10,700 such deaths among women.

The cancer type with the highest prevalence rate in Latin America and the Caribbean in 2022 was breast cancer, with 213.1 cases per 100,000 population. This was followed by prostate cancer and colorectal cancer, with prevalence rates of 175.8 and 61.3 cases per 100,000 population, respectively. That year, breast and prostate cancer were also the two cancer types with the highest mortality rates in the region. Regional variations in cancer prevalence While breast cancer has a higher prevalence rate in Latin America overall, individual countries show distinct patterns. Uruguay stands out with the highest age-standardized cancer prevalence rates in Latin America and the Caribbean for both men and women, at 1,331.5 and 1,301.6 cases per 100,000 population as of 2022, followed by Barbados, Cuba, and Argentina. When it comes to differences between genders, while some countries like Chile and Cuba show higher rates among men, most nations in the region report higher prevalence rates among women.
Medical equipment for diagnosis and treatment Like prevalence rates, the availability of specialized medical equipment used for cancer diagnosis and treatment in Latin American hospitals varies from country to country and from technology to technology. As of 2023, while one in four hospitals in the region had CT scanners, only one percent had robotic surgery systems. When it comes to basic equipment, ECG and ultrasound machines are the most common type of equipment found in Latin American hospitals.

As of 2021, non-Hispanic white people in the United States had the highest incidence rates of skin cancer among all races and ethnicities. Skin cancer is one of the most commonly occurring cancers in the world. Furthermore, the United States is among the countries with the highest rates of skin cancer worldwide. Skin cancer in the U.S. There are a few different types of skin cancer and some are more deadly than others. Basal and squamous skin cancers are more common and less dangerous than melanomas. Among U.S. residents, skin cancer has been demonstrated to be more prevalent among men than women. Skin cancer is also more prevalent among older adults. With treatment and early detection, skin cancers have a high survival rate. Fortunately, in recent years the U.S. has seen a reduction in the rate of death from melanoma. Skin cancer prevention Avoiding and protecting exposed skin from the sun (and other sources of UV light) is the primary means of preventing skin cancer. However, a survey of U.S. adults from 2024 found that around a third never used sunscreen.

Some racial and ethnic categories are suppressed for privacy and to avoid misleading estimates when the relative standard error exceeds 30% or the unweighted sample size is less than 50 respondents. Margins of error are estimated at the 90% confidence level.

Data Source: Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey (BRFSS) Data

Why This Matters

Colorectal cancer is the third leading cause of cancer death in the U.S. for men and women. Although colorectal cancer is most common among people aged 65 to 74, there has been an increase in incidences among people aged 40 to 49.

Nationally, Black people are disproportionately likely to both have colorectal cancer and die from it. Hispanic residents, and especially those with limited English proficiency, report having the lowest rate of colorectal cancer screenings.

Racial disparities in education, poverty, health insurance coverage, and English language proficiency are all factors that contribute to racial gaps in receiving colorectal cancer screenings. Increased colorectal cancer screening utilization has been shown to nearly erase the racial disparities in the death rate of colorectal cancer.

The District Response

The Colorectal Cancer Control Program (DC3C) aims to reduce colon cancer incidence and mortality by increasing colorectal cancer screening rates among District residents.

DC Health’s Cancer and Chronic Disease Prevention Bureau works with healthcare providers to improve the use of preventative health services and provide colorectal cancer screening services.

DC Health maintains the District of Columbia Cancer Registry (DCCR) to track cancer incidences, examine environmental substances that cause cancer, and identify differences in cancer incidences by age, gender, race, and geographical location.

Snapshot img

Bladder Cancer Market Size 2024-2028

The bladder cancer market size is forecast to increase by USD 2.45 billion at a CAGR of 11.4% between 2023 and 2028.

Bladder cancer is a significant health concern, with minimally invasive surgical procedures, such as robotic-assisted surgery and laparoscopic treatments, gaining popularity due to their benefits in reducing post-operative complications and recovery time.
Additionally, the market is witnessing advancements in non-invasive diagnostics, including liquid biopsy, which offers early detection and recurrence monitoring for advanced-stage bladder cancer patients. New drug approvals are driving market growth, while concerns over product recalls remain a challenge for companies. This report provides a comprehensive analysis of market trends, growth drivers, and challenges in the market.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

Bladder cancer is a type of urinary tract cancer that affects the tissues lining the inside of the bladder. This malignancy encompasses various subtypes, including urothelial carcinoma, adenocarcinoma, and transitional cell carcinoma. In the United States, bladder cancer ranks among the top ten most common cancers, with an estimated 81,190 new cases and 17,240 deaths in 2021, according to the Cancer Observatory. Despite advancements in diagnostics and therapeutics, bladder cancer remains a significant challenge due to factors such as detection delays and ineffective biomarkers. The healthcare industry is dedicated to addressing these issues and improving patient outcomes through innovative approaches.
Additionally, nanobots, a promising technology, have emerged as a potential solution for early detection and targeted treatment of bladder cancer. These tiny robots can navigate through the urinary system, identifying and targeting cancer cells without harming healthy cells. Intravesical treatment, a common approach for superficial bladder cancer, involves administering anti-cancer drugs directly into the bladder. Chemotherapy and immunotherapy are the primary therapeutic methods for invasive bladder cancer. Immunotherapy, specifically immune checkpoint inhibitors, has shown promising results in clinical trials, with increasing adoption in the healthcare sector. Diagnostic techniques play a crucial role in the early detection and successful treatment of bladder cancer.
Moreover, cystoscopy, urine cytology, and biomarker tests are the primary methods for diagnosing bladder cancer. However, persistent bladder infections can complicate the diagnostic process, necessitating a thorough evaluation to distinguish between infection and cancer. Radiation therapy and immunotherapy are essential components of bladder cancer treatment. While radiation therapy destroys cancer cells using high-energy radiation, immunotherapy harnesses the power of the immune system to target and eliminate cancer cells. Despite these advancements, challenges remain in the market. Detection delays and ineffective biomarkers continue to impact patient outcomes. The healthcare industry must focus on improving diagnostic accuracy and developing more effective biomarkers to enhance early detection and improve treatment outcomes.
In conclusion, the market is driven by the need for innovative diagnostics and therapeutics to address the challenges of detection delays and ineffective biomarkers. Technologies such as nanobots, intravesical treatment, and immunotherapy are leading the way in the development of advanced solutions for bladder cancer. The healthcare sector must continue to invest in research and development to improve patient outcomes and ultimately, conquer this formidable disease. 

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Disease Type

  Transitional cell carcinoma
  Others


Drug Class

  Immunotherapy drugs
  Chemotherapy drugs
  Target therapy drugs


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy
    Spain


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By Disease Type Insights

The transitional cell carcinoma segment is estimated to witness significant growth during the forecast period.

Bladder cancer, specifically Transitional Cell Carcinoma (TCC), originates from the urothelial cells that line the interior of the bladder and other parts of the urinary tract, including the renal pelvis, ureters, and urethra. This type of cancer, also known as urothelial carcinoma, accounts for the majority of bladder cancer cases and is a significant focus in the global market for bladder cancer treatments. TCC can man

It was estimated that in 2025 around 313,780 men in the United States would develop prostate cancer. This statistic depicts the estimated number of new cancer cases among men in the U.S. in 2009 and 2025, by cancer type.

Market Size and Drivers: The global skin cancer diagnostics market is projected to reach $9.58 billion by 2033, expanding at a CAGR of 5.52%. The increasing incidence of skin cancer, growing awareness of early detection, and technological advancements are driving market growth. Melanoma and non-melanoma skin cancers account for significant segments, with advances in dermatoscopy and imaging tests enhancing diagnostic accuracy. Rising healthcare expenditure and government initiatives to promote early diagnosis further contribute to market expansion. Trends, Restraints, and Key Players: Key market trends include the rise of artificial intelligence (AI) and machine learning (ML) in skin cancer diagnosis, improving efficiency and precision. Telemedicine and remote diagnostics are also gaining momentum, extending access to healthcare services. However, challenges such as false negatives in skin biopsies and cost limitations restrain market growth. Prominent players in the market include Castle Bioscience, DermTech, bioMérieux, Inc., and Quest Diagnostics Incorporated., with ongoing research and product development aiming to enhance diagnostic capabilities and patient outcomes. Skin Cancer Diagnostics Market: A Comprehensive Report Executive Summary The global skin cancer diagnostics market is poised to reach USD 15 billion by 2029, exhibiting a CAGR of 6.5% from 2021 to 2029. The increasing prevalence of skin cancer, advancements in diagnostic technologies, and rising awareness about early detection drive market growth. Recent developments include: In February 2024, Quest Diagnostics launched MelaNodal Predict, a highly advanced predictive gene expression test to help personalize treatment decisions for patients with melanoma, the deadliest form of skin cancer and one of the most common cancers in the U.S. , In January 2024, DermaSensor Inc. received FDA clearance for its noninvasive skin cancer assessment system, which uses artificial intelligence to detect common skin cancers, such as melanoma, basal cell carcinoma, and SCC. The wireless, handheld device provides instant, objective results using an FDA-approved algorithm, allowing physicians to evaluate suspicious lesions without invasive procedures. , In January 2024, SkylineDx, a diagnostics technology developer, received European Patent No. 3827101, a significant advancement in cancer diagnostics and personalized treatment. The patent outlines novel methods for categorizing and managing patients with primary cutaneous melanoma, using gene expression signature levels. .

Death rate has been age-adjusted by the 2000 U.S. standard population. Single-year data are only available for Los Angeles County overall, Service Planning Areas, Supervisorial Districts, City of Los Angeles overall, and City of Los Angeles Council Districts.Lung cancer is a leading cause of cancer-related death in the US. People who smoke have the greatest risk of lung cancer, though lung cancer can also occur in people who have never smoked. Most cases are due to long-term tobacco smoking or exposure to secondhand tobacco smoke. Cities and communities can take an active role in curbing tobacco use and reducing lung cancer by adopting policies to regulate tobacco retail; reducing exposure to secondhand smoke in outdoor public spaces, such as parks, restaurants, or in multi-unit housing; and improving access to tobacco cessation programs and other preventive services.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

Market Overview:

The 7 major nonmelanoma skin cancer markets reached a value of US$ 467.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 621.3 Million by 2034, exhibiting a growth rate (CAGR) of 2.62% during 2024-2034.

Report Attribute	Key Statistics
Base Year	2023
Forecast Years	2024-2034
Historical Years	2018-2023
Market Size in 2023	US$ 467.4 Million
Market Forecast in 2034	US$ 621.3 Million
Market Growth Rate (2024-2034)	2.62%

The nonmelanoma skin cancer market has been comprehensively analyzed in IMARC's new report titled "Nonmelanoma Skin Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Nonmelanoma skin cancer refers to a group of skin cancers that develop from the basal cells or squamous cells of the skin, excluding melanocytes. The most common symptom is the formation of an abnormal growth or lesion on the skin that may vary in size, shape, color, or texture over time. Basal cell carcinoma (BCC), the most prevalent type of nonmelanoma skin cancer, include symptoms like small, shiny, or raised bumps, pink/red patches, and non-healing sores that might bleed or crust. Squamous cell carcinoma (SCC), the second most common disease type, often appears as scaly, red/pink elevated growths that may develop a crust or ulcerate. The diagnostic process usually begins with a thorough examination of the skin, focusing on any suspicious lesions. The healthcare provider will assess the characteristics of the lesion, such as its size, shape, texture, etc. If a suspicious area is identified, skin biopsy can be performed. Various additional procedures, including imaging scans and sentinel lymph node biopsy, are also recommended in some instances to determine the extent of the cancer.

https://www.imarcgroup.com/CKEditor/f3513b55-cb8e-4079-a5ac-4541ea27a319nonmelanoma-skin-cancer-market-report-(1).webp" style="height:450px; width:800px" />

The increasing cases of prolonged exposure to UV radiation that lead to abnormal cell growth and the development of cancerous lesions are primarily driving the nonmelanoma skin cancer market. Besides this, the rising prevalence of several associated risk factors, including weakened immune system, chronic skin inflammation, family history, use of indoor tanning beds or sunlamps, etc., is acting as another significant growth-inducing factor. Furthermore, the escalating usage of Mohs micrographic surgery for treating large, aggressive, or recurrent cancererous cells or those located in cosmetically sensitive areas is also bolstering the market growth. Additionally, the emerging popularity of cryosurgery, which involves freezing nonmelanoma skin cancer cells with liquid nitrogen, is creating a positive outlook for the market. The freezing destroys the abnormal cells, leading to their sloughing off and subsequent healing. Moreover, the inflating demand for immune checkpoint inhibitors, such as pembrolizumab and nivolumab, to enhance the body's immune response against malignant cells is also augmenting the market growth. Apart from this, the increasing application of electronic brachytherapy for treating lesions since it minimizes damage to surrounding tissues, thereby preserving aesthetics and resulting in better cosmetic outcomes compared to other invasive procedures, is expected to drive the nonmelanoma skin cancer market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the nonmelanoma skin cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for nonmelanoma skin cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the nonmelanoma skin cancer market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
  

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the nonmelanoma skin cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the nonmelanoma skin cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current nonmelanoma skin cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Drugs	Company Name
Keytruda (Pembrolizumab)	Merck & Co
Libtayo (Cemiplimab)	Regeneron Pharmaceuticals
Bavencio (Avelumab)	Avelumab
EscharEx	MediWound
AIV001	AiViva BioPharma
STP705	Sirnaomics
Patidegib	Sol-Gel Technologies
LTX315	Lytix Biopharma

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the nonmelanoma skin cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the nonmelanoma skin cancer market across the seven major markets in 2023 and what will it look like in 2034?
<li

Snapshot img

Breast Cancer Therapeutics Market Size 2024-2028

The breast cancer therapeutics market size is forecast to increase by USD 15.64 bn at a CAGR of 8.4% between 2023 and 2028.

The market is experiencing significant growth due to the rising prevalence of breast cancer and the emergence of novel therapeutics. Hormone therapy and radiation therapy continue to be popular treatment options, while oncology drugs such as monoclonal antibodies, biosimilars, and vaccines are gaining popularity. Artificial intelligence is revolutionizing cancer diagnostics and treatment plans, enabling early detection and personalized treatment. Online pharmacies and telemedicine are making treatments more accessible, especially in remote areas. The high cost of treatment remains a challenge, but education and nutrition programs are helping to mitigate this issue. Protein-based therapies, gelatin, and tablets are also key components of breast cancer therapeutics.In the US, the market is expected to grow steadily due to increasing awareness and advancements in technology and treatment methods.

What will be the Size of the Breast Cancer Therapeutics Market During the Forecast Period?

Request Free SampleThe market encompasses a range of treatments designed to combat this prevalent form of cancer among females. Key therapeutic approaches include chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. Oncology drugs and therapeutics play a pivotal role in addressing breast cancer, targeting various proteins and cells, such as milk ducts, milk-producing lobules, and tumors. Breast cancer awareness initiatives and screening programs are instrumental in early detection, leading to improved patient outcomes. Artificial intelligence and advanced diagnostics are increasingly utilized to enhance the accuracy of diagnoses, enabling more effective interventions. Breast cancer can manifest as lumps, red patches, pain, swelling, or symptoms affecting the nipple, bones, breathing, or lymph nodes.Surgical tumor removal and medications, including hormonal therapies, are essential components of treatment plans. Despite advancements, breast cancer continues to pose significant health challenges, with ongoing research and innovation required to address the complexities of this disease.

How is this Breast Cancer Therapeutics Industry segmented and which is the largest segment?

The breast cancer therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. Disease TypeInvasive breast cancersDuctal carcinoma in situTherapyTargeted therapyHormonal therapyChemotherapyGeographyNorth AmericaCanadaUSEuropeGermanyUKAsiaChinaRest of World (ROW)

By Disease Type Insights

The invasive breast cancers segment is estimated to witness significant growth during the forecast period. Invasive ductal carcinoma, also known as infiltrating ductal carcinoma, is the most prevalent type of breast cancer, accounting for approximately 80% of diagnoses. This form of cancer arises when cancerous cells invade the fibrous or fatty tissue of the breast beyond the milk ducts. Symptoms include breast swelling, skin irritation, pain, nipple discomfort, redness, and nipple discharge, among others. Risk factors include genetics, hormonal imbalances, obesity, alcohol intake, and prior radiation therapy. Hormonal therapies, such as tamoxifen and aromatase inhibitors, chemotherapy, radiation therapy, targeted therapies, including Herceptin for HER2-positive tumors, and immunotherapies are common treatments. Early detection through breast cancer awareness campaigns, screening programs, and regular self-examinations contribute to improved survival probabilities and reduced morbidity.The development of oncology drugs and therapeutics, including proteins and biosimilars, continues to advance treatment options. Government support, hospital visits, and recovery rates are crucial aspects of breast cancer care. Hormonal therapy, obesity, and family history are significant factors in cancer type analysis. Hospital pharmacies and online pharmacies provide access to medications.

Get a glance at the market report of various segments Request Free Sample

The Invasive breast cancers segment was valued at USD 22.55 bn in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The North American the market is experiencing significant growth due to the availability of r

Snapshot img

Glioblastoma Multiforme Treatment Market Size 2024-2028

The glioblastoma multiforme treatment market size is forecast to increase by USD 1.36 billion at a CAGR of 8.2% between 2023 and 2028.

The glioblastoma multiforme (GBM) treatment market is experiencing significant growth due to the rising incidence of this aggressive brain cancer and increasing research and development activities In the healthcare sector. According to the American Brain Tumor Association's Cancer Observatory, GBM accounts for approximately 15% of all primary brain tumors and is the most common malignant brain tumor in adults. Current treatment options include surgery, targeted therapy, and chemotherapy. Surgery remains the primary treatment modality for GBM, with various options such as awake craniotomy and awake craniotomy with intraoperative monitoring. This includes various strategies such as checkpoint inhibitors, monoclonal antibodies, and gene therapy. However, these procedures come with adverse effects such as cognitive impairment and motor deficits. Targeted therapies, such as temozolomide, are used in conjunction with surgery and chemotherapy to improve patient outcomes. The pharmaceutical supply chain plays a crucial role in ensuring the timely availability of these treatments to patients. Despite advancements in treatment options, the high mortality rate associated with GBM necessitates continued research and development efforts to improve patient outcomes and quality of life.

What will be the Size of the Glioblastoma Multiforme Treatment Market During the Forecast Period?

Request Free Sample

Glioblastoma multiforme (GBM), a malignant tumor of the central nervous system (CNS), is a significant health concern worldwide. According to the Global Cancer Observatory, CNS cancers accounted for approximately 2.3% of all cancer diagnoses and 2.5% of cancer deaths in 2020. This article provides an overview of the current treatment landscape for GBM, focusing on surgical, radiation, chemotherapy, targeted therapy, immunotherapy, and emerging novel therapies. Surgery is the primary treatment modality for GBM, with the primary goal being to remove as much of the tumor as possible while minimizing damage to healthy brain tissue. Ambulatory surgical centers and hospitals offer various surgical procedures, including craniotomy and awake craniotomy. Following surgery, patients typically undergo radiation therapy to target any remaining cancer cells. External beam radiation therapy (EBRT) is the most common approach, delivering high-energy radiation to the tumor site. Chemotherapy is often used in combination with radiation therapy to enhance the therapeutic effect.
Moreover, temozolomide, a chemotherapeutic agent, is the most widely used drug for GBM treatment. Corticosteroids, such as dexamethasone, are also frequently administered to reduce swelling and improve symptoms. Targeted therapies, such as bevacizumab, are designed to specifically target the molecular mechanisms of GBM. These therapies inhibit the growth and spread of cancer cells by blocking the action of specific proteins. Moreover, combination Therapies: Combination therapies, which involve the use of multiple treatment modalities, are increasingly being explored to improve treatment outcomes for GBM. For example, the combination of temozolomide and radiation therapy has been shown to improve survival rates compared to monotherapy. Immunotherapy: Immunotherapy, which harnesses the power of the immune system to fight cancer, is an emerging treatment approach for GBM. Personalized Medicine: The heterogeneity of GBM necessitates personalized treatment approaches.
Thus, drug classes and treatment procedures are being tailored to individual patients based on their unique tumor characteristics, such as genetic mutations and protein expression profiles. The treatment market for GBM is continually evolving, with a focus on developing novel therapies and combination strategies to improve patient outcomes. The pharmaceutical supply chain plays a crucial role in ensuring the availability and accessibility of these treatments. As the understanding of GBM biology deepens, so too will the range and effectiveness of treatment options.

How is this Glioblastoma Multiforme Treatment Industry segmented and which is the largest segment?

The glioblastoma multiforme treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Hospitals
  Clinics
  Ambulatory surgical centers


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By End-user Insights

The hospitals segment is estimated to witness significant growth during the forecast period.

It is estimated that around 280,000 new cases of cancer will be diagnosed in Spain during 2023, of which 160,000 are expected in men and 120,000 in women. Breast cancer is expected to be the type with the highest incidence in the country, with more than 35,000 new cases estimated for 2023, followed by lung and prostate cancer with 31,282 and 29,002 cases, respectively.

Cancer-related deaths

In 2021, cancer was responsible for approximately 114,000 deaths in Spain. Lung and bronchial cancer caused the highest number of cancer deaths in the country, accounting for approximately 22,400 terminal cases. In fact, it was the fourth main cause of death overall, only after COVID-19, coronary artery disease (CAD), and cerebrovascular disease. Lung cancer is highly associated with smoking and is therefore among the most preventable diseases.

Most common types of cancer worldwide

Breast cancer is the most common type of cancer among women in the world. In 2020, around a quarter of all new cancer cases within this group was attributed to breast cancer. Colorectum and lung cancer followed, accounting for 9.4 and 8.4 percent of all new cancer cases among women that year, respectively. In comparison, lung cancer was the most common type of cancer among men, with a share of 14.3 percent. Prostate cancer followed closely, with 14.1 percent.

Dataset Card for Breast Ultrasound Images Dataset

  Dataset Summary

Breast cancer is one of the most common causes of death among women worldwide. Early detection helps in reducing the number of early deaths. The data reviews the medical images of breast cancer using ultrasound scan. Breast Ultrasound Dataset is categorized into three classes: normal, benign, and malignant images. Breast ultrasound images can produce great results in classification, detection, and… See the full description on the dataset page: https://huggingface.co/datasets/ShivamRaisharma/breastcancer.

Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. This report focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for prostate cancer. . Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreon’s Provenge, Sanofi’s Jevtana, Johnson & Johnson’s Zytiga, Medivation/Astellas’ Xtandi, and Bayer’s Xofigo. During the forecast period from 2013-2023, GlobalData expects that nine new late-stage pipeline agents will launch, eight of which will be for the treatment of CRPC. As a result of this unprecedented level of clinical development, GlobalData predicts there will be massive changes in the CRPC treatment paradigm. In addition, due to the influx of new therapies, the size of the prostate cancer market across the nine major pharmaceutical markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase three-fold. The 5EU is the second largest market for prostate cancer, after the US. This strong growth will be a result of the increasing incidence of prostate cancer as the population ages, increased sales resulting from the launch of eight new premium-priced pipeline products during the forecast period, and the label extension of Xtandi into the nmCRPC and hormone-sensitive prostate cancer patient populations. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Read More

Snapshot img

Radiation Oncology Market Size 2024-2028

The radiation oncology market size is forecast to increase by USD 1.94 billion at a CAGR of4.34% between 2023 and 2028.

In the market, the primary drivers include the increasing incidence of cancer and the rise in healthcare expenditure. As cancer continues to be a significant health concern, the demand for advanced radiation therapy techniques, such as seeds and stereotactic therapy, is increasing. These treatments offer therapeutic benefits by targeting abnormal cells with precision, reducing the impact on healthy cells. Technological developments, including advanced treatment planning software, tumor tracking systems, artificial intelligence, and machine learning, enable more effective and personalized treatment plans. However, challenges persist, including the lack of access to radiotherapy in certain regions and the high cost of these advanced treatments. Despite these challenges, the market is expected to grow, driven by the potential for improved patient outcomes and the ongoing technological advancements In the field.

What will be the Size of the Radiation Oncology Market During the Forecast Period?

Request Free Sample

The market is a significant segment of the healthcare industry, focusing on the delivery of radiation therapy to treat various types of cancer. This form of oncology treatment, also known as radiotherapy, utilizes high-energy radiation to destroy tumor cells. Radiation oncology plays a crucial role in cancer treatment, with breast cancer, metastatic melanoma, and neuroendocrine cancers being some of the common indications. The increasing prevalence of cancer and the growing demand for advanced therapeutic benefits have driven the market's growth. Regulatory scrutiny remains a critical factor In the market.



Stringent regulations ensure the safety and efficacy of radiotherapy devices and treatment planning software. These regulations also apply to advanced technologies like proton therapy, which offers improved therapeutic benefits for certain types of cancer. Imaging data plays a pivotal role in radiation oncology. Accurate and timely access to imaging data is essential for effective treatment planning and delivery. Cancer treatment centers and oncology research institutes are investing in advanced imaging technologies to enhance their capabilities. Technological developments in radiation oncology are continually evolving. Companies are focusing on improving the precision, efficiency, and patient experience of radiotherapy. Radiotherapy devices, such as those manufactured by Elekta and Gamma Knife, are being enhanced with innovative features.

How is this Radiation Oncology Industry segmented and which is the largest segment?

The radiation oncology industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  EBRT
  Brachytherapy


Application

  Breast cancer
  Lung cancer
  Penile cancer
  Prostate cancer
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Type Insights

The EBRT segment is estimated to witness significant growth during the forecast period.

Radiation oncology, a specialized medical field focusing on the use of radiation to treat various types of cancer, encompasses external beam radiation therapy (EBRT). EBRT utilizes high-energy beams, typically generated by a Linear Accelerator (LINAC, the most common technology), to target and destroy cancer cells. These beams can be delivered as X-rays, electrons, or other particles, such as protons. EBRT plays a crucial role in treating numerous cancer types, including breast cancer, colorectal cancer (CRC), cervical cancer, esophageal cancer, head and neck cancer, lung cancer, prostate cancer, and brain tumors. Advanced radiotherapy systems, such as CyberKnife, Gamma Knife, and TomoTherapy, are also part of the EBRT market.

Furthermore, proton therapy, which uses cyclotrons and synchrotrons, is another subset of EBRT. Among these technologies, LINAC holds the largest market share In the market. By providing precise and effective cancer treatment, these advanced technologies contribute significantly to cancer treatment centers across the US and North America, ensuring improved patient outcomes and quality of life.

Get a glance at the Radiation Oncology Industry report of share of various segments Request Free Sample

The EBRT segment was valued at USD 6.22 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

Europe is estimated to contribute 39% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends

Snapshot img

Head And Neck Cancer Diagnostics Market Size 2024-2028

The head and neck cancer diagnostics market size is forecast to increase by USD 6.3 billion at a CAGR of 13.64% between 2023 and 2028.

The market is experiencing significant growth due to the rising incidences of head and neck cancers. This trend is driven by the increasing awareness and early detection of these cancers, leading to a higher demand for accurate and efficient diagnostic tools. Additionally, the use of immunotherapy in head and neck cancer treatment is on the rise, necessitating advanced diagnostic methods to identify the presence of these cancers and determine the most effective treatment options. However, frequent product recalls due to safety concerns and regulatory issues pose a challenge to market growth. It is essential for market players to address these challenges by ensuring stringent quality control measures and adhering to regulatory guidelines to maintain consumer trust and confidence.

What will be the Size of the Head And Neck Cancer Diagnostics Market during the Forecast Period?

Request Free SampleThe market encompasses a range of diagnostic procedures and devices used to identify various types of cancer In the head and neck region, including oropharyngeal and throat cancer. Key diagnostic tools include physical exams, biopsies, and imaging modalities such as endoscopy, MRI, CT, PET/CT, chest imaging, and diagnostic devices. Radiologists and pathologists play crucial roles in interpreting these diagnostic results. Novel technologies, such as molecular and genetic testing, are also gaining traction In the market. The market is experiencing significant growth due to increasing cancer incidences worldwide, a growing focus on early detection, and rising healthcare expenditure. Personal healthcare spending and hospital spending on cancer treatment are major drivers of market growth.Diagnostic imaging and prescription drugs are significant components of the market, while dental care is also becoming increasingly relevant due to the link between oral health and head and neck cancers.

How is this Head And Neck Cancer Diagnostics Industry segmented and which is the largest segment?

The head and neck cancer diagnostics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. Diagnostic MethodsBiopsy and blood testsImagingEndoscopyDental diagnosticsEnd-userHospitalsSpecialty clinicsAmbulatory surgical centersOthersGeographyNorth AmericaUSEuropeGermanyFranceAsiaChinaJapanRest of World (ROW)

By Diagnostic Methods Insights

The biopsy and blood tests segment is estimated to witness significant growth during the forecast period. The global head and neck cancer diagnostic market is primarily driven by the prevalence of oropharyngeal cancer and thyroid nodule assessment. Biopsy and blood tests are the largest diagnostic segments due to their significance in confirming cancer diagnoses. A biopsy involves the removal of tissue or cells for laboratory analysis, with incisional biopsies being commonly used for oral cancer diagnosis. Diagnostic imaging techniques, including endoscopy, MRI, CT, PET/CT, and chest imaging, complement biopsies in identifying cancerous growths. Diagnostic devices, genomic testing, tumor sequencing, molecular profiling, and genetic mutation analysis are emerging technologies in head and neck cancer diagnostics. Reimbursement issues and economic strategies pose challenges to market growth.Early detection and advancements in targeted therapy and immunotherapy are significant trends. Key players In the market include Viome Life Science, CancerDetect, GE Healthcare, and others. Skilled physicians, software technologies, and telemedicine are transforming diagnostic practices. Healthcare expenditure, prescription drugs, dental care, sedentary lifestyle, and chronic diseases contribute to market demand.

Get a glance at the market report of various segments Request Free Sample

The Biopsy and blood tests segment was valued at USD 1.64 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The market in North America is expected to dominate the global landscape due to the region's high incidence of head and neck cancers, particularly In the US. Notable market participants, such as GE Healthcare and Varian Medical Systems, are headquartered In the US, ensuring the availability of advanced diagnostic equipment.